Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 03:06 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
MisOpRostol Effect on Second Trimester Abortion Blood Loss
NCT06078501 · Stanford University · PHASE3 · terminated · last registry update 2025-08-24 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Recruitment not feasible for this patient population within study timeframe” | – | Registry record, Stanford University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PTGER3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-05-08Phase 3 first posted: Indiana University, Cervical ripening with a double balloon catheter plus misoprostol + Usual-care control group (NCT07576881)
- 2026-04-01Phase 3 first posted: University of Pennsylvania, 200mg mifepristone and 800mg misoprostol (NCT07506512)
- 2026-03-27Also stopped (terminated): Assistance Publique - Hôpitaux de Paris, Misoprostol (NCT01113229)
- 2026-03-18Results posted on the registry: Washington University School of Medicine, Mifepristone + Misoprostol (NCT05322252)
- 2026-02-24Phase 3 first posted: Udayana University, Bilateral ESPB: Ropivacaine 0.375% + Dexamethasone 5mg + Bilateral ESPB: Ropivacaine 0.375% (NCT07429708)
- 2026-01-26Also stopped (terminated): Baylor Research Institute, Pitocin (NCT02910115)
- 2026-01-20Also stopped (terminated): University of California, San Francisco, Misoprostol (NCT04940013)
- 2025-11-17Results posted on the registry: Hackensack Meridian Health, Prophylactic use of ibuprofen and ondansetron post misoprostol administration + Use of ibuprofen and ondansetron at symptom onset post misoprostol administration (NCT05819619)
- 2025-11-17Also stopped (terminated): Hackensack Meridian Health, Prophylactic use of ibuprofen and ondansetron post misoprostol administration + Use of ibuprofen and ondansetron at symptom onset post misoprostol administration (NCT05819619)
- 2025-09-04Also stopped (withdrawn): Institut National de la Santé Et de la Recherche Médicale, France, Prostaglandin E2 (NCT00545194)
- 2025-07-29Results posted on the registry: The University of Texas Health Science Center at San Antonio, Misoprostol 200Mcg Tab + Placebo (NCT03064568)
- 2025-06-06Also stopped (withdrawn): University of Chicago, a drug against PTGER3 (NCT06456164)
- 2025-01-17Also stopped (terminated): Hospital Kemaman, Intravaginal prostaglandin E2 (NCT05622968)
- 2025-01-09Phase 3 first posted: Assiut University, Misoprostol (NCT06765473)
- 2024-08-28Also stopped (terminated): University Hospital, Limoges, Dinoprostone + Oxytocine (NCT02888041)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision